Cathie Wood's Ark Invest sold shares of five biotech and healthcare companies in recent trades. She also offloaded over 1.1 ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

The global sales of DNA polymerase are estimated to be worth USD 397.7 million in 2025 and anticipated to reach a value of ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

The inaugural TCCI AI-Driven Science Symposium was held in San Francisco from Monday to Tuesday, bringing together three ...

Xenotransplantation is the fusion energy of medicine. As the well-worn joke goes, it is the future—and always will be. But ...

ICHORtec GmbH is pleased to announce an expanded research collaboration with the laboratory of Professor Gregory A. Newby in the Department of Genetic Medicine at the Johns Hopkins University School ...

Mutations in ZRSR2 have been linked with disease progression in patients with JAK2 V617R – driven myeloproliferative neoplasms (MPNs), but a new report suggests that loss of ZRSR2 alone is not ...